No products in the cart.
Return To ShopNo products in the cart.
Return To ShopNo products in the cart.
Return To ShopNo products in the cart.
Return To ShopBRILINTA 90 MG, a product of AstraZeneca, is an antiplatelet medication primarily comprised of the active ingredient ticagrelor. The formulation is specifically designed to inhibit platelet aggregation, which is crucial for preventing thrombus formation in patients with acute coronary syndromes. Each tablet contains 90 mg of ticagrelor, along with various inactive ingredients that aid in the tablet’s stability and bioavailability.
The pharmacological action of BRILINTA revolves around its unique mechanism of inhibition of adenosine diphosphate (ADP) receptors on the platelet surface. Unlike traditional thienopyridine agents, such as clopidogrel, BRILINTA acts in a reversible manner. This feature allows it to provide a quicker onset of action and a shorter duration, effectively reducing the risk of cardiovascular events in susceptible individuals. The fast-acting nature of ticagrelor makes it particularly beneficial for patients undergoing percutaneous coronary interventions.
In the realm of sports pharmacology, the utilization of BRILINTA 90 MG may offer several benefits, particularly for athletes with underlying cardiovascular concerns or those recovering from cardiac events. Here’s why some athletes consider it:
While the advantages of using BRILINTA in sports may sound appealing, it is crucial for athletes to consult with healthcare professionals before considering this medication, as individual circumstances vary widely.
BRILINTA 90 MG is available through various pharmacies and can also be purchased securely online. It’s essential to obtain BRILINTA from authorized suppliers to ensure the authenticity of the product. Patients should look for licensed online pharmacies that require a valid prescription to guarantee safe and effective sourcing.
When purchasing online, consider the following:
– Verify that the website is reputable and has appropriate accreditation.
– Read reviews and ratings from previous customers.
– Ensure that customer service is accessible for inquiries and support.
– Check for secure payment options to protect personal information.
Taking these steps can help ensure that you receive genuine BRILINTA while avoiding counterfeit products that may pose serious health risks.
Despite its benefits, BRILINTA 90 MG is not without potential side effects. Commonly reported issues include shortness of breath, headache, dizziness, and gastrointestinal disturbances such as nausea. More serious concerns encompass an increased risk of bleeding, which could lead to serious complications like hemorrhage.
To manage these risks:
– Monitor for any signs of unusual bleeding, including prolonged bleeding from cuts, increased bruising, or blood in urine or stool.
– Communicate openly with healthcare providers about any pre-existing conditions, particularly bleeding disorders or history of stroke.
– Conduct regular follow-ups to assess the medication’s effectiveness and any side effects experienced.
– Abandon usage if any severe reactions occur and seek immediate medical attention.
Awareness and proactive management are crucial in mitigating risks while implementing any medication in a sports setting.
In conclusion, while BRILINTA 90 MG AstraZeneca holds substantial promise for enhancing cardiovascular safety in athletes, responsible usage and professional guidance are paramount. Athletes should carefully evaluate their health needs and consult with healthcare providers to determine if this medication aligns with their training regimens and health goals. Making informed decisions will foster not only immediate performance benefits but also long-term cardiovascular health.
| Active substance | Ticagrelor |
|---|---|
| Water Retention | None |
| Hepatotoxicity | Low risk |
| Lab Test | Not specific, may monitor platelet function tests |
| Also known as | AZD6140 |
| Blood pressure | Can cause transient increase |
| Trade name | Brilinta, Brilique, Possia |
| FORM | 56 pills x 90 mg |
| Storage conditions | Store at room temperature away from moisture and heat |
| Chemical name | (1S,2S,3R,5R)-3-[7-[(1R,2S)-2-(3,4-Difluorophenyl)cyclopropylamino]-5-(propylthio)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl]-5-(2-hydroxyethoxy)cyclopentane-1,2-diol |
| Formula | C23H28F2N6O4S |
| Substance class | Antiplatelet agent |
| Main action | Platelet aggregation inhibitor |
| Half-life | Approximately 7 to 8.5 hours |
| Dosage (medical) | Typically 90 mg twice daily |
| Dosage (sports) | Not applicable |
| Effects | Reduces the rate of stent thrombosis in patients who are at risk, decreases myocardial infarction |
| Side effects | Bleeding, dyspnea, headache, cough, hypertension, nausea |
| Use in sports | Not typically used in sports |
| Manufacturer | AstraZeneca |
€106.00
€75.00
Select at least 2 products
to compare
Reviews
There are no reviews yet.